mRECIST outcomes in EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization plus durvalumab with/without bevacizumab in participants with embolization-eligible hepatocellular carcinoma Meeting Abstract
| Authors: | Sangro, B.; Kudo, M.; Erinjeri, J.; Qin, S.; Ren, Z.; Chan, S.; Arai, Y.; Heo, J.; Mai, A.; Escobar, J.; Chuken, Y. A. L.; Yoon, J. H.; Tak, W. Y.; Suttichaimongkol, T.; Bouattour, M.; Lin, S. M.; Żotkiewicz, M.; Ali, S.; Cohen, G.; Lencioni, R. |
| Abstract Title: | mRECIST outcomes in EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization plus durvalumab with/without bevacizumab in participants with embolization-eligible hepatocellular carcinoma |
| Meeting Title: | European Association for the Study of the Liver (EASL) Congress 2024 |
| Journal Title: | Journal of Hepatology |
| Volume: | 80 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2024 Jun 5-8 |
| Meeting Location: | Milan, Italy |
| ISSN: | 0168-8278 |
| Publisher: | Elsevier Science, Inc. |
| Date Published: | 2024-06-01 |
| Start Page: | S3 |
| Language: | English |
| ACCESSION: | WOS:001278309400006 |
| PROVIDER: | wos |
| DOI: | 10.1016/S0168-8278(24)00428-8 |
| Notes: | Meeting Abstract: GS-005 -- Source: Wos |
